Friday 6 November 2026 Export TVTX’s income statement to Excel — free account

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.

Revenue: +36.2%
EPS: −290.7%
Free cash flow: +6,379.8%
Total debt: +93.8%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

49.45 0.58 +1.19%

Follow TVTX

Alert me

Market cap: $4.7B
P/E: 0.0×
Fwd P/E: −145×
Dividend yield: —
F-score: 6/9
Altman Z: 1.78
Beneish M: −1.74
Dividend safety: n/a

Overview

Travere Therapeutics, Inc. (TVTX) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Travere Therapeutics, Inc. (TVTX) trades at a P/S ratio of 7.2×. Over the past ten years it has ranged from 2.4× (March 2020) to 21.5× (March 2015); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 9.4× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TVTX/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Travere Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TVTX/metrics/ps-ratio">Travere Therapeutics, Inc. (TVTX) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	6.9×	17.86%
FY2024	5.9×	20.56%
FY2023	4.9×	(59.38%)
FY2022	12.0×	(14.57%)
FY2021	14.1×	115.58%
FY2020	6.5×	90.57%
FY2019	3.4×	(38.45%)
FY2018	5.6×	(0.92%)
FY2017	5.6×	10.04%
FY2016	5.1×	(21.16%)

Period	P/S ratio	Change
Sep 2026	8.6×	(4.70%)
Jun 2026	9.0×	76.42%
Mar 2026	5.1×	(26.72%)
Dec 2025	6.9×	41.96%
43 more quarters	Free account

Against its own ten years

Low 2.4× High 21.5×

Ten-year median 6.3×

Current reading's percentile 73

Company	P/S ratio
EWTX Edgewise Therapeutics, Inc. compare	n/m
DFTX Definium Therapeutics, Inc. compare	n/m
ERAS Erasca, Inc. compare	n/m
MANE Veradermics Incorporated compare	n/m
LEGN Legend Biotech Corporation Sponsored ADR compare	3.4×
TVTX Travere Therapeutics, Inc.	7.2×
CRSP CRISPR Therapeutics AG compare	192×
COGT Cogent Biosciences, Inc. compare	233×
DNTH Dianthus Therapeutics, Inc. compare	1,823×
Biotechnology industry median	9.4×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Travere Therapeutics, Inc. (TVTX) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on TVTX

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on TVTX

Stockrow Weekly